Dicerna Pharmaceuticals Inc 4
4 · Dicerna Pharmaceuticals Inc · Filed Feb 4, 2014
Insider Transaction Report
Form 4
SCHOEMAKER KATHLEEN K
10% Owner
Transactions
- Conversion
Warrant
2014-02-04−21,041→ 0 total(indirect: By Domain Partners VIII, L.P.)Exercise: $7.00From: 2014-01-29Exp: 2018-06-26→ Series C Preferred Stock (21,041 underlying) - Conversion
Warrant
2014-02-04−156→ 0 total(indirect: By DP VIII Associates, L.P.)Exercise: $7.00From: 2014-01-29Exp: 2018-06-26→ Series C Preferred Stock (156 underlying) - Conversion
Common Stock
2014-02-04+13,004→ 13,004 total(indirect: By DP VIII Associates, L.P.) - Conversion
Series B Preferred Stock
2014-02-04−476,464→ 0 total(indirect: By Domain Partners VIII, L.P.)→ Common Stock (476,464 underlying) - Conversion
Series C Preferred Stock
2014-02-04−1,276,243→ 0 total(indirect: By Domain Partners VIII, L.P.)→ Common Stock (1,276,243 underlying) - Conversion
Series B Preferred Stock
2014-02-04−3,535→ 0 total(indirect: By DP VIII Associates, L.P.)→ Common Stock (3,535 underlying) - Conversion
Series C Preferred Stock
2014-02-04−9,469→ 0 total(indirect: By DP VIII Associates, L.P.)→ Common Stock (9,469 underlying) - Conversion
Common Stock
2014-02-04+1,752,707→ 1,752,707 total(indirect: By Domain Partners VIII, L.P.) - Conversion
Warrant
2014-02-04+21,041→ 21,041 total(indirect: By Domain Partners VIII, L.P.)Exercise: $7.00From: 2014-01-29Exp: 2018-06-26→ Common Stock (21,041 underlying) - Conversion
Warrant
2014-02-04+156→ 156 total(indirect: By DP VIII Associates, L.P.)Exercise: $7.00From: 2014-01-29Exp: 2018-06-26→ Common Stock (156 underlying)
Footnotes (2)
- [F1]All outstanding shares of preferred stock were automatically converted into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration. The preferred stock had no expiration date.
- [F2]The Reporting Person is a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.